Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor

Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor

Submitted by admin on February 10, 2023 - 11:09am
Source: 
Fierce Pharma
News Tags: 
Galapagos
FDA
filgotinib
Crohn's Disease
clinical trials
Jyseleca
Headline: 
Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor
snippet: 

After a phase 3 trial flop, Galapagos’ JAK1 preferential inhibitor filgotinib won't be launching in Crohn’s disease anytime soon.

Do Not Allow Advertisers to Use My Personal information